In 2020, Roche, the world’s largest biotech company and global investor in R&D is expected to lose US sales worth $2.5 billion as a result of biosimilar competition.
IMARC Group, in its new report “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)” finds that five of the Roche’s blockbuster biologicals (Avastin, Herceptin, Mabthera, Lucentis and Xolair) face biosimilar competition during 2011-2020. Projections from the report that are based on a primary and secondary research suggest that the combined sales of these five drugs will decline from $10.7 billion in 2010 to $8.2 billion in 2020.
Despite this significant decline, Roche is still expected to be much better off than some of its other peers such as Amgen – at least in the short term. Findings from the study suggest the excluding Mabthera, the company’s other four brands will face biosimilar competition only during 2019-2020. As a result, Roche will suffer most of its brand erosion post-2020. The study finds that unlike Roche, Amgen is expected to witness biosimilar competition in all four of its brands (Enbrel, Epogen, Neupogen, and Neulasta) during 2013-2015. Projections from the report suggest that the combined sales of these four products will reduce from $10.6 billion in 2010 to just $1.4 billion in 2020.
IMARC’s new report entitled provides an analytical and statistical insight into the US biosimilar market. The study, that has been undertaken using desk-based as well as qualitative primary research, provides and draws upon analysis of six aspects of the US biosimilar market.
Editor’s comment: These numbers come from a detailed report but the world is changing so fast. The report is based on the US as it is the major market in the world but the growth rate in the emerging markets will have a chance to change this in the near future. USA is under economic pressure by all means like most of the other developed countries and these projections will definitely change till 2020.
Besides, biosimilars market is changing so rapidly. It’s mentioned in the report that, only Mabthera will face biosimilar attack before 2019 but biosimilar versions of Herceptin will also be launched around 2015 in the US. Very recently, Amgen announced a new patent for Enbrel and even this new information will change the numbers which were published in this report.
We are not trying to criticize this extensive work and we are sure the full report has lots of detailed information about biosimilars in the US but just wanted to give you some “up to date information” as it is our motto here at BiosimilarNews.com.
Source: IMARC Group press release (www.imarcgroup.com)